Literature DB >> 8794805

Effect of omeprazole on movement of intravenously administered metronidazole into gastric juice and its significance in treatment of Helicobacter pylori.

S J Veldhuyzen van Zanten1, P T Pollak, H Kapoor, P K Yeung.   

Abstract

Four healthy, Helicobacter-negative volunteers were studied to determine the effect of omeprazole on the movement of metronidazole across the gastric mucosa into the gastric lumen. Each received a 500-mg intravenous infusion of metronidazole and repeated serum, and gastric juice samples were obtained concomitantly over an 8-hr study via indwelling intravenous catheter and nasogastric tube. The same protocol was repeated following one week of oral omeprazole 20 mg twice daily. Metronidazole concentrations were measured by high-performance liquid chromatography. The results demonstrated that: metronidazole moves rapidly from serum into gastric juice; omeprazole causes a marked reduction in total metronidazole concentrations in gastric juice, completely accounted for by pH-related shifts in the proportion of ionized metronidazole, but does not alter concentrations of nonionized metronidazole, which remain above the MIC level against H. pylori; and even under conditions where no pH-related drug trapping occurs (pH > 4), concentrations of metronidazole were higher in gastric juice than in serum during most of the study, indicating that a special transport mechanism may be operational. The practical implication of this effect of omeprazole in combination therapy with metronidazole remains to be established.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8794805     DOI: 10.1007/bf02088756

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  22 in total

1.  Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori.

Authors:  T Iwahi; H Satoh; M Nakao; T Iwasaki; T Yamazaki; K Kubo; T Tamura; A Imada
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

2.  Pharmacokinetics of metronidazole in saliva.

Authors:  S Suryawati; B Santoso
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1991-12

3.  In vivo susceptibility of Campylobacter pylori.

Authors:  D Y Graham; P D Klein; A R Opekun; K E Smith; R R Polasani; D J Evans; D G Evans; L C Alpert; P A Michaletz; H H Yoshimura
Journal:  Am J Gastroenterol       Date:  1989-03       Impact factor: 10.864

4.  One week eradication regimen for Helicobacter pylori.

Authors:  R P Logan; P A Gummett; J J Misiewicz; Q N Karim; M M Walker; J H Baron
Journal:  Lancet       Date:  1991-11-16       Impact factor: 79.321

5.  pH and Hp--gastric acid secretion and Helicobacter pylori: implications for ulcer healing and eradication of the organism.

Authors:  R H Hunt
Journal:  Am J Gastroenterol       Date:  1993-04       Impact factor: 10.864

6.  Secretion of intravenously administered antibiotics in gastric juice: implications for management of Helicobacter pylori.

Authors:  S J van Zanten; J Goldie; J Hollingsworth; C Silletti; H Richardson; R H Hunt
Journal:  J Clin Pathol       Date:  1992-03       Impact factor: 3.411

7.  A liquid chromatography assay for the study of serum and gastric juice metronidazole concentrations in the treatment of Helicobacter pylori.

Authors:  P T Pollak
Journal:  Ther Drug Monit       Date:  1996-12       Impact factor: 3.681

8.  The proton pump inhibitor omeprazole inhibits acid survival of Helicobacter pylori by a urease-independent mechanism.

Authors:  C C McGowan; T L Cover; M J Blaser
Journal:  Gastroenterology       Date:  1994-11       Impact factor: 22.682

9.  Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers.

Authors:  E Bayerdörffer; S Miehlke; G A Mannes; A Sommer; W Höchter; J Weingart; W Heldwein; H Klann; T Simon; W Schmitt
Journal:  Gastroenterology       Date:  1995-05       Impact factor: 22.682

10.  Long-term omeprazole therapy does not affect Helicobacter pylori status in most patients.

Authors:  E J Kuipers; E C Klinkenberg-Knol; H P Festen; C B Lamers; J B Jansen; P Snel; F Nelis; S G Meuwissen
Journal:  Scand J Gastroenterol       Date:  1993-11       Impact factor: 2.423

View more
  5 in total

1.  Pharmacodynamic effects of nitroimidazoles alone and in combination with clarithromycin on Helicobacter pylori.

Authors:  Margareta Svensson; Lennart E Nilsson; Magnus Ström; Maud Nilsson; Mikael Sörberg
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

Review 2.  Pharmacokinetic considerations in the eradication of Helicobacter pylori.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

3.  Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study.

Authors:  F Mégraud; N Lehn; T Lind; E Bayerdörffer; C O'Morain; R Spiller; P Unge; S V van Zanten; M Wrangstadh; C F Burman
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

4.  Effect of acid secretion blockade by omeprazole on the relative bioavailability of orally administered furazolidone in healthy volunteers.

Authors:  S A Calafatti; R A Ortiz; M Deguer; M Martinez; J Pedrazzoli
Journal:  Br J Clin Pharmacol       Date:  2001-08       Impact factor: 4.335

5.  Gastric transitional zones, areas where Helicobacter treatment fails: results of a treatment trial using the Sydney strain mouse model.

Authors:  Sander J O Veldhuyzen van Zanten; Tassia Kolesnikow; Vincent Leung; Jani L O'Rourke; Adrian Lee
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.